Total Funding
1
65
Total FundingVenture - Series Unknown raised
Growth Score
-10 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
771265
Fulcrum Pharmaceuticals is a privately held drug design and development company.
Evan Dick: Held PositionPast Role: Kereos, Team Member- Douglas Gessl: Vice President of Finance
About the Company
Fulcrum Pharmaceuticals applies computational chemistry, structural biology and thermodynamics to achieve accelerated design and development of drug products. Founded in 2002, Fulcrum has developed a portfolio of proprietary lead compounds targeted at inflammatory disease, osteoporosis, infectious disease and oncology. This portfolio includes small
molecule inhibitors of receptors and enzymes, small molecule mimics of antibodies and receptors, and "adaptive" anti-infectives (drugs capable of overcoming resistance). Fulcrum's strategy is to out-license a portion of its pipeline, while retaining selected compounds for internal development. For more information, visit www.fulcrumpharmaceuticals.com.
